The Multiple Sclerosis Modulatory Potential of Natural Multi-Targeting Antioxidants

Molecules. 2022 Dec 1;27(23):8402. doi: 10.3390/molecules27238402.

Abstract

Multiple sclerosis (MS) is a complex neurodegenerative disease. Although its pathogenesis is rather vague in some aspects, it is well known to be an inflammatory process characterized by inflammatory cytokine release and oxidative burden, resulting in demyelination and reduced remyelination and axonal survival together with microglial activation. Antioxidant compounds are gaining interest towards the manipulation of MS, since they offer, in most of the cases, many benefits, due to their pleiotropical activity, that mainly derives from the oxidative stress decrease. This review analyzes research articles, of the last decade, which describe biological in vitro, in vivo and clinical evaluation of various categories of the most therapeutically applied natural antioxidant compounds, and some of their derivatives, with anti-MS activity. It also summarizes some of the main characteristics of MS and the role the reactive oxygen and nitrogen species may have in its progression, as well as their relation with the other mechanistic aspects of the disease, in order for the multi-targeting potential of those antioxidants to be defined and the source of origination of such activity explained. Antioxidant compounds with specific characteristics are expected to affect positively some aspects of the disease, and their potential may render them as effective candidates for neurological impairment reduction in combination with the MS treatment regimen. However, more studies are needed in order such antioxidants to be established as recommended treatment to MS patients.

Keywords: antioxidant bioactive compounds; inflammation; multiple sclerosis; natural antioxidants; neurodegeneration; oxidative stress.

Publication types

  • Review

MeSH terms

  • Antioxidants / metabolism
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Humans
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis* / pathology
  • Neurodegenerative Diseases* / drug therapy
  • Oxidation-Reduction
  • Oxidative Stress / physiology

Substances

  • Antioxidants

Grants and funding

This research received no external funding.